Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 219

Sort by

Sort Order Select

Journal Articles

JAK2/mTOR Inhibition Fails to Prevent Acute GVHD Despite Reduced Th1/Th17 cells: Final Phase II Trial Results

Blood blood.2024024789.

https://doi.org/10.1182/blood.2024024789

Published: 2024

Includes: Supplemental data

Journal Articles

BCL11B Modulates Hemogenic Endothelium-Derived Multipotent Hematopoietic Progenitors and Enhances Myeloid and Lymphoid Pathways from Human iPSCs

Akhilesh Kumar, Colin Fischer, Alexander Lenvik, Ojas Singh, Jeffrey S Miller, Frank Cichocki

Blood (2023) 142 (Supplement 1): 2684.

https://doi.org/10.1182/blood-2023-188760

Published: 2023

Journal Articles

A Pan-Cancer Single-Cell Transcriptomic Atlas of Natural Killer (NK) Cells Reveals Intrinsic and Extrinsic Mediators of NK Cell Anti-Tumor Functions

John R Lozada, Atef Ali, Abderrahman Day, Jacob A Myers, Ella Boytim, Hannah Bergom, Nicholas Zorko, Martin Felices, Jeffrey S Miller, Justin Hwang, Frank Cichocki

Blood (2023) 142 (Supplement 1): 2547.

https://doi.org/10.1182/blood-2023-187347

Published: 2023

Journal Articles

Simvastatin with Intrathecal Dexamethasone Reduces Neurotoxicity in Adults Receiving Chimeric Antigen Receptor (CAR) T-Cells Treatment

Nuttavut Sumransub, Cassie Seichter, Kateryna Kent, Ryan Shanley, Marie Hu, Daniel O'Leary, Najla H El Jurdi, Shernan G. Holtan, Brian Betts, Mark Juckett, Jeremy R. Allred, Veronika Bachanova, Jeffrey S Miller, Joseph E. Maakaron

Blood (2023) 142 (Supplement 1): 3493.

https://doi.org/10.1182/blood-2023-187070

Published: 2023

Journal Articles

JAK2/mTOR Inhibition Fails to Prevent Acute Gvhd Despite Reduced Th1/Th17 Cells: Final Phase II Trial Results

Joseph Pidala, Shernan G. Holtan, Kelly Walton, Jongphil Kim, Hany Elmariah, Asmita Mishra, Nelli Bejanyan, Taiga Nishihori, Farhad Khimani, Lia Perez, Rawan Faramand, Marco Davila, Claudio Anasetti, Daniel Weisdorf, Bruce R Blazar, Jeffrey S Miller, Veronika Bachanova, Najla H El Jurdi, Brian C Betts

Blood (2023) 142 (Supplement 1): 2177.

https://doi.org/10.1182/blood-2023-173376

Published: 2023

Journal Articles

Phase I Study of FT538 + Daratumumab for Treatment of r/r AML

Joseph E. Maakaron, Cassie Seichter, Rose Wangen, Andrea Hoeschen, Deepa Kolaseri Krishnadas, Kateryna Kent, Ryan Shanley, Daniel O'Leary, Najla H El Jurdi, Shernan G. Holtan, Brian Betts, Mark Juckett, Jeffrey S Miller

Blood (2023) 142 (Supplement 1): 4842.

https://doi.org/10.1182/blood-2023-189132

Published: 2023

Journal Articles

Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies

Frank Cichocki, Sjoukje J. C. van der Stegen, Jeffrey S. Miller

Blood (2023) 141 (8): 846–855.

https://doi.org/10.1182/blood.2022016205

Published: 2023

Journal Articles

Dual antigen–targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia

Blood (2022) 140 (23): 2451–2462.

https://doi.org/10.1182/blood.2021015184

Published: 2022

Includes: Supplemental data

Journal Articles

B7-H3 Trike Enhances Killing of Myeloid Derived Suppressor Cells in Multiple Myeloma

Aimee Merino, Hayden Hamsher, Daniel Mansour, Gregory I. Berk, Martin Felices, Jeffrey S. Miller, MD

Blood (2022) 140 (Supplement 1): 8851–8852.

https://doi.org/10.1182/blood-2022-162566

Published: 2022

Journal Articles

A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogenous Population Associated with AML

Zachary Davis, Frank Cichocki, Martin Felices, Hongbo Wang, Peter Hinderlie, Mark Juckett, Joseph Maakaron, Gregory I. Berk, Bryan Hancock, John Goulding, Ryan Bjordahl, Bahram Valamehr, Jeffrey S. Miller, MD

Blood (2022) 140 (Supplement 1): 10288–10289.

https://doi.org/10.1182/blood-2022-168981

Published: 2022

Journal Articles

Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate

Blood (2022) 140 (Supplement 1): 282–283.

https://doi.org/10.1182/blood-2022-165782

Published: 2022

Journal Articles

Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy

Blood (2022) 139 (8): 1177–1183.

https://doi.org/10.1182/blood.2021011532

Published: 2022

Includes: Supplemental data

Journal Articles

Low Incidence of Chronic Graft-Versus-Host Disease in Myeloablative Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Using Matched Related or Unrelated Donors: Phase II Study Interim Analysis

Blood (2021) 138 (Supplement 1): 1811.

https://doi.org/10.1182/blood-2021-147569

Published: 2021

Journal Articles

Icans Prophylaxis with Simvastatin and Intrathecal Dexamethasone in Adults Receiving Axicabtagene Ciloleucel (Axi‐Cel) Treatment

Joseph Maakaron, Emily Stene, Megan Bruns, Todd E. DeFor, Najla H El Jurdi, Veronika Bachanova, Daniel J. Weisdorf, Jeffrey S. Miller, Murali Janakiram, Mark Juckett

Blood (2021) 138 (Supplement 1): 1744.

https://doi.org/10.1182/blood-2021-149607

Published: 2021

Journal Articles

Gda-201, a Novel Metabolically Enhanced Allogeneic Natural Killer (NK) Cell Product Yields High Remission Rates in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL): 2-Year Survival and Correlation with Cytokine IL7

Veronika Bachanova, Joseph E. Maakaron, Frank Cichocki, David H. McKenna, Qing Cao, Todd E. DeFor, Murali Janakiram, Rose Wangen, Zuzan Cayci, Bartosz Grzywacz, Ronit Simantov, Tracey Lodie, Jeffrey S. Miller

Blood (2021) 138 (Supplement 1): 3854.

https://doi.org/10.1182/blood-2021-149989

Published: 2021

Journal Articles

A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy of Cmvpepvax for Preventing CMV Reactivation/Disease after Matched Related/Unrelated Donor Hematopoietic Cell Transplant

Blood (2021) 138 (Supplement 1): 2887.

https://doi.org/10.1182/blood-2021-153312

Published: 2021

Journal Articles

KIR-HLA Interactions Lack Clinical Utility in Matched Unrelated Donor Transplantation for AML: An Analysis of the CIBMTR and DRST Registries

Joshua A Fein, Roni Shouval, Elizabeth Krieger, Henning Baldauf, Katharina Fleischhauer, Nicolaus Kroeger, Mary M. Horowitz, Martin Maiers, Karl-Johan Malmberg, Jeffrey S. Miller, Mohamad Mohty, Arnon Nagler, Rizwan Romee, Johannes Schetelig, Stephen R. Spellman, Amir Ahmed Toor, Tao Wang, Daniel J. Weisdorf, John Koreth

Blood (2021) 138 (Supplement 1): 419.

https://doi.org/10.1182/blood-2021-149935

Published: 2021

Journal Articles

Arming of iPSC-Derived NK Cells Expressing a Novel CD64 Fusion Receptor with Therapeutic Antibodies Represents a Novel Off-the-Shelf, Antigen-Targeting Strategy for Cancer

Kate Dixon, Kristin Snyder, Melissa Khaw, Robert Hullsiek, Zachary Davis, Tom Lee, Hui-yi Chu, Paul Rogers, Ryan Bjordahl, Martin Hosking, Soheila Shirinbak, Jeffrey S. Miller, Bahram Valamehr, Jianming Wu, Bruce Walcheck

Blood (2021) 138 (Supplement 1): 406.

https://doi.org/10.1182/blood-2021-148642

Published: 2021

Journal Articles

Off-the-Shelf, Multiplexed-Engineered iPSC-Derived NK Cells Mediate Potent Multi-Antigen Targeting of B-Cell Malignancies with Reduced Cytotoxicity Against Healthy B Cells

Blood (2021) 138 (Supplement 1): 407.

https://doi.org/10.1182/blood-2021-148654

Published: 2021

Journal Articles

Initial Clinical Activity of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma

Veronika Bachanova, MD PhD, Zuzan Cayci, MD, Dixie Lewis, RN,BA, Joseph E. Maakaron, MD, Murali Janakiram, MD, Andersen Bartz, Steven Payne, BS, Carol Wong, MPH, Sarah Cooley, MD, Bahram Valamehr, PhD, Yu-Waye Chu, MD, Jeffrey S. Miller, MD

Blood (2020) 136 (Supplement 1): 8.

https://doi.org/10.1182/blood-2020-141606

Published: 2020

NARROW

JAK2/mTOR Inhibition Fails to Prevent Acute GVHD Despite Reduced Th1/Th17 cells: Final Phase II Trial Results

BCL11B Modulates Hemogenic Endothelium-Derived Multipotent Hematopoietic Progenitors and Enhances Myeloid and Lymphoid Pathways from Human iPSCs

A Pan-Cancer Single-Cell Transcriptomic Atlas of Natural Killer (NK) Cells Reveals Intrinsic and Extrinsic Mediators of NK Cell Anti-Tumor Functions

Simvastatin with Intrathecal Dexamethasone Reduces Neurotoxicity in Adults Receiving Chimeric Antigen Receptor (CAR) T-Cells Treatment

JAK2/mTOR Inhibition Fails to Prevent Acute Gvhd Despite Reduced Th1/Th17 Cells: Final Phase II Trial Results

Phase I Study of FT538 + Daratumumab for Treatment of r/r AML

Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies

Dual antigen–targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia

B7-H3 Trike Enhances Killing of Myeloid Derived Suppressor Cells in Multiple Myeloma

A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogenous Population Associated with AML

Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate

Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy

Low Incidence of Chronic Graft-Versus-Host Disease in Myeloablative Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Using Matched Related or Unrelated Donors: Phase II Study Interim Analysis

Icans Prophylaxis with Simvastatin and Intrathecal Dexamethasone in Adults Receiving Axicabtagene Ciloleucel (Axi‐Cel) Treatment

Gda-201, a Novel Metabolically Enhanced Allogeneic Natural Killer (NK) Cell Product Yields High Remission Rates in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL): 2-Year Survival and Correlation with Cytokine IL7

A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy of Cmvpepvax for Preventing CMV Reactivation/Disease after Matched Related/Unrelated Donor Hematopoietic Cell Transplant

KIR-HLA Interactions Lack Clinical Utility in Matched Unrelated Donor Transplantation for AML: An Analysis of the CIBMTR and DRST Registries

Arming of iPSC-Derived NK Cells Expressing a Novel CD64 Fusion Receptor with Therapeutic Antibodies Represents a Novel Off-the-Shelf, Antigen-Targeting Strategy for Cancer

Off-the-Shelf, Multiplexed-Engineered iPSC-Derived NK Cells Mediate Potent Multi-Antigen Targeting of B-Cell Malignancies with Reduced Cytotoxicity Against Healthy B Cells

Initial Clinical Activity of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only